Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs

Eur J Ophthalmol. 2014 Sep-Oct;24(5):771-7. doi: 10.5301/ejo.5000455. Epub 2014 Mar 19.

Abstract

Purpose: To assess the efficacy of a hypotensive prophylactic medication in preventing intraocular pressure (IOP) changes after intravitreal injections, and the effect of occurrence of vitreous reflux on the variation of IOP.

Methods: A total of 141 intravitreal injections of anti-vascular endothelial growth factor drugs (0.05 mL) were randomly distributed into 2 groups: in group 1 (n = 77), no prophylactic IOP-lowering medication was used; in group 2 (n = 64), a fixed combination of brimonidine and timolol was instilled 5 minutes before the injection. The IOP was measured before and 1, 15, and 30 minutes after the injection. The presence of vitreous reflux was recorded.

Results: Despite significantly reducing the IOP by ~3 mm Hg, prophylactic medication did not prevent a transient IOP rise. A total of 22.7% of injections showed vitreous reflux, and those patients experienced much lower initial spikes. Indeed, only 6.5% out of 77 injections above 30 mm Hg within 1 minute after injection showed vitreous reflux. Only one case showed an IOP >30 mm Hg at 15 minutes, and none at 30 minutes postinjection. The IOP normalization rates over time were similar in all groups within 15 minutes.

Conclusions: Prophylactic medication instilled 5 minutes before the injection was not effective in preventing a pressure rise after intravitreal injections. Vitreous reflux decreased significantly the spike figures compared to injections with no reflux.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antihypertensive Agents / administration & dosage*
  • Bevacizumab
  • Brimonidine Tartrate
  • Drug Combinations
  • Eye Diseases
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Ocular Hypertension / etiology
  • Ocular Hypertension / prevention & control*
  • Pressure
  • Prospective Studies
  • Quinoxalines / administration & dosage
  • Ranibizumab
  • Retinal Diseases / drug therapy*
  • Timolol / administration & dosage
  • Tonometry, Ocular
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitreous Body / pathology*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antihypertensive Agents
  • Drug Combinations
  • Quinoxalines
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Brimonidine Tartrate
  • Timolol
  • Ranibizumab